Recruiting studies: High Risk Muscle Invasive Urothelial Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours
Phase 4 · 1 location(s) · University of Roma La Sapienza · NCT05962541 Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence
Phase 2 · 1 location(s) · University of California, Irvine · NCT06682728 DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC
Phase 3 · 1 location(s) · Fudan University · NCT07207824 EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC
Phase 2 · 1 location(s) · Peking University Third Hospital · NCT07647289 A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants
Phase 2 · 107 location(s) · Hoffmann-La Roche · NCT06534983 An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With
Phase 3 · 160 location(s) · AstraZeneca · NCT07720284 Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive B
Phase 3 · 6 location(s) · Verity Pharmaceuticals Inc. · NCT05037279 A Multicenter Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Mi
Phase N/A · 1 location(s) · Peking University First Hospital · NCT06991868 Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Partici
Phase 3 · 6 location(s) · Protara Therapeutics · NCT07480356 Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
Phase 2/Phase 3 · 1 location(s) · Vasgene Therapeutics, Inc · NCT06493552 Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
Phase 2 · 1 location(s) · Michael A. O'Donnell · NCT07322263 Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy T
Phase 2 · 134 location(s) · National Cancer Institute (NCI) · NCT06770582

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.